NIVEN RALPH 4

Accession 0001415889-24-002957

CIK 0001798749other

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 6:00 PM ET

Size

20.2 KB

Accession

0001415889-24-002957

Form 4

Period: 2024-02-05

Chief Development Officer

Transactions

Exercise/Conversion
Common Stock
2024-02-05$1.74/sh+1,400$2,436→ 3,009 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−1,200→ 34,908 total
Exercise: $2.14Exp: 2031-04-01→ Common Stock (1,200 underlying)
Exercise/Conversion
Common Stock
2024-02-05$2.14/sh+3,200$6,848→ 6,209 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−500→ 10,894 total
Exercise: $2.14Exp: 2031-04-01→ Common Stock (500 underlying)
Sale
Common Stock
2024-02-05$17.45/sh−4,600$80,249→ 1,609 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−900→ 13,308 total
Exercise: $1.74Exp: 2030-09-03→ Common Stock (900 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−500→ 9,088 total
Exercise: $1.74Exp: 2030-09-03→ Common Stock (500 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-05−1,500→ 41,732 total
Exercise: $2.14Exp: 2031-04-01→ Common Stock (1,500 underlying)

Footnotes (7)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
[F3]A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
[F4]A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
[F5]A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
[F6]A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
[F7]A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

Documents

1 file

Aerovate Therapeutics, Inc.

CIK 0001798749

Entity typeother